Demyelinating diseases in Asia

Current Opinion in Neurology

Volumn 29, Issue 3, 2016, Pages 222-228

  Ochi, Hirofumi ^a   Fujihara, Kazuo ^b  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

aquaporin 4 antibody; multiple sclerosis; myelin oligodendrocyte glycoprotein antibody; neuromyelitis optica neuromyelitis optica spectrum disorder

Indexed keywords

AQUAPORIN 4 ANTIBODY; CHOLESTEROL 7ALPHA MONOOXYGENASE; HLA DPB1 ANTIGEN; HLA DRB1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ALLELE; ASIA; CLINICAL RESEARCH; CONUS MEDULLARIS; CUBA; DEMYELINATING DISEASE; DENMARK; DIFFERENTIAL DIAGNOSIS; ENVIRONMENTAL FACTOR; ETHNICITY; GENETIC SUSCEPTIBILITY; GENOME-WIDE ASSOCIATION STUDY; GEOGRAPHY; HONG KONG; HUMAN; INDIA; JAPAN; KOREA; MALAYSIA; MYELITIS; MYELOOPTIC NEUROPATHY; OPTIC CHIASM; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PREVALENCE; PROMOTER REGION; REGISTER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPINAL CORD LESION; THAILAND; UNITED KINGDOM; UNITED STATES; ANIMAL; MULTIPLE SCLEROSIS;

ANIMALS; ASIA; DEMYELINATING DISEASES; HUMANS; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA;

EID: 84963682325     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000328     Document Type: Review

References (64)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372:1502-1517.
2. Atlas of MS 2013. Mapping multiple sclerosis around the world. http://www.msif.org [Accessed 22 December 2015].
3. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003; 2:117-127.
4. Chang KH, Lyu RK, Chen CM, et al. Clinical characteristics of multiple sclerosis in Taiwan: a cross-sectional study. Mult Scler 2006; 12:501-506.
5. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106-2112.
6. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis bindstothe aquaporin-4 water channel.JExp Med 2005; 202:473-477.
7. Marignier R, Nicolle A, Watrin C, et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 2010; 133:2578-2591.
8. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66:630-643.
9. Pittock SJ, Lucchinetti CF. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci 2015. [Epub ahead of print]
10. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuro-myelitis optica. Lancet Neurol 2007; 6:805-815.
11. Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 2012; 1:180-187.
12. Nakashima I, Fukazawa T, Ota K, et al. Two subtypes of optic-spinal form of multiple sclerosis in Japan: clinical and laboratory features. J Neurol 2007; 254:488-492.
13. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 2013; 80:2194-2200.
14. Bernard-Valnet R, Liblau RS, Vukusic S, Marignier R. Neuromyelitis optica: a positive appraisal of seronegative cases. Eur J Neurol 2015; 22:1511-1518.
15. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013; 81:1197-1204.
16. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 6:383-392.
17. Takahashi T, Fujihara K, Nakashima I, et al. Antiaquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130:1235-1243.
18. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012; 78:665-671.
19. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85:177-189.
20. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012; 9:14.
21. Ketelslegers IA, Modderman PW, Vennegoor A, et al. Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and mono-phasic patients. Mult Scler 2011; 17:1527-1530.
22. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012; 79:1273-1277.
23. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011; 8:184.
24. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82:474-481.
25. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71:276-283.
26. Heydarpour P, Khoshkish S, Abtahi S, et al. Multiple sclerosis epidemiology in Middle East and North Africa: a systematic review and meta-analysis. Neuroepidemiology 2015; 44:232-244.
27. Cheng Q, Miao L, Zhang J, et al. A population-based survey of multiple sclerosis in Shanghai, China. Neurology 2007; 68:1495-1500.
28. Lai CH, Tseng HF. Population-based epidemiological study of neurological diseases in Taiwan: I. Creutzfeldt-Jakob disease and multiple sclerosis. Neuroepidemiology 2009; 33:247-253.
29. Kim NH, Kim HJ, Cheong HK, et al. Prevalence of multiple sclerosis in Korea. Neurology 2010; 75:1432-1438.
30. Miyamoto K. Epidemiology of neuromyelitis optica [in Japanese]. Nihon Rinsho 2015; 73 (Suppl 7):260-264.
31. Pandit L, Kundapur R. Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Mult Scler 2014; 20:1651-1653.
32. Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler 2015; 21:845-853.
33. Viswanathan S, Rose N, Masita A, et al. Multiple sclerosis in Malaysia: demographics, clinical features, and neuroimaging characteristics. Mult Scler Int 2013; 2013:614716.
34. Osoegawa M, Kira J, Fukazawa T, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler 2009; 15:159-173.
35. Sawcer S, Franklin RJ, Ban M. Multiple sclerosis genetics. Lancet Neurol 2014; 13:700-709.
36. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004; 3:104-110.
37. Qiu W, James I, Carroll WM, et al. HLA-DR allele polymorphism and multiple sclerosis in Chinese populations: a meta-analysis. Mult Scler 2011; 17:382-388.
38. Yoshimura S, Isobe N, Yonekawa T, et al. Genetic and infectious profiles of Japanese multiple sclerosis patients. PLoS One 2012; 7:e48592.
39. McElroy JP, Isobe N, Gourraud PA, et al. SNP-based analysis of the HLA locus in Japanese multiple sclerosis patients. Genes Immun 2011; 12:523-530.
40. Yoshimura S, Isobe N, Matsushita T, et al. Genetic and infectious profiles influence cerebrospinal fluid IgG abnormality in Japanese multiple sclerosis patients. PLoS One 2014; 9:e95367.
41. Yamasaki K, Horiuchi I, Minohara M, et al. HLA-DPB1∗0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain 1999; 122:1689-1696.
42. Matsushita T, Matsuoka T, Isobe N, et al. Association of the HLA-DPB1∗0501 allele with antiaquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. Tissue Antigens 2009; 73:171-176.
43. Wang H, Dai Y, Qiu W, et al. HLA-DPB1 0501 is associated with susceptibility to antiaquaporin-4 antibodies positive neuromyelitis optica in southern Han Chinese. J Neuroimmunol 2011; 233:181-184.
44. Zephir H, Fajardy I, Outteryck O, et al. Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler 2009; 15:571-579.
45. Deschamps R, Paturel L, Jeannin S, et al. Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population. Mult Scler 2011; 17:24-31.
46. Brum DG, Barreira AA, dos Santos AC, et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult Scler 2010; 16:21-29.
47. Kim HJ, Park HY, Kim E, et al. Common CYP7A1 promoter polymorphism associated with risk of neuromyelitis optica. Neurobiol Dis 2010; 37:349-355.
48. Zhao GX, Liu Y, Li ZX, et al. Variants in the promoter region of CYP7A1 are associated with neuromyelitis optica but not with multiple sclerosis in the Han Chinese population. Neurosci Bull 2013; 29:525-530.
49. Kim SH, Huh SY, Kim W, et al. Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations? Mult Scler 2013; 19:1493-1498.
50. Chen SY, Lo CP, Hsu WL, et al. Modifications to the McDonald MRI dissemination in space criteria for use in Asians with classic multiple sclerosis: the Taiwanese experience. Mult Scler 2010; 16:1213-1219.
51. Huh SY, Kim SH, Kim W, et al. Evaluation of McDonald MRI criteria for dissemination in space in Korean patients with clinically isolated syndromes. Mult Scler 2014; 20:492-495.
52. Piccolo L, Kumar G, Nakashima I, et al. Multiple sclerosis in Japan appears to be a milder disease compared to the UK. J Neurol 2015; 262:831-836.
53. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology 2010; 74:2004-2015.
54. Jena SS, Alexander M, Aaron S, et al. Natural history of multiple sclerosis from the Indian perspective: experience from a tertiary care hospital. Neurol India 2015; 63:866-873.
55. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012; 135:1834-1849.
56. Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoanti-body-associated demyelinating diseases. Nat Rev Neurol 2013; 9:455-461.
57. Hoftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2015; 21:866-874.
58. Siritho S, Sato DK, Kaneko K, et al. The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients. Mult Scler 2015. [Epub ahead of print]
59. Ramanathan S, Prelog K, Barnes EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 2015. [Epub ahead of print]
60. Probstel AK, Rudolf G, Dornmair K, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroin-flammation 2015; 12:46.
61. van Pelt ED, Wong YY, Ketelslegers IA, et al. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. Eur J Neurol 2016; 23:580-587.
62. Miyazawa I, Fujihara K, Itoyama Y. Neuromyelitis optica (Devic disease) and optic-spinal form multiple sclerosis [in Japanese]. No To Shinkei 2001; 53:901-910.
63. Akaishi T, Sato DK, Nakashima I, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry 2015. [Epub ahead of print]
64. Kim SM, Woodhall MR, Kim JS, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2015; 2:e163.